Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

ObjectivePreclinical studies have emphasized the potential connection between BRCA specific domains defects and the activity of Poly ADP-ribose polymerase inhibitors (PARPi). Nevertheless, real-world evidence regarding the impact of BRCA domain defects and mutations on PARPi efficacy are limited. Th...

詳細記述

書誌詳細

主要な著者:	Roberto Buonaiuto, Giuseppe Neola, Aldo Caltavituro, Alessandra Longobardi, Federica Pia Mangiacotti, Amedeo Cefaliello, Maria Rosaria Lamia, Francesco Pepe, Jole Ventriglia, Umberto Malapelle, Giancarlo Troncone, Mario Giuliano, Grazia Arpino, Sandro Pignata, Carmine De Angelis
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2024-09-01
シリーズ:	Frontiers in Oncology
主題:	HGSOC PARP inhibitors BRCA mutation domain resistance ovarian cancer
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1412807/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!